SCHMERTZLER MICHAEL

Average Profitability
49.41%
Insider Buys Quantity
6
Insider Buys Sum
$17.21M
Insider Sells Quantity
10
Insider Sells Sum
$6.41M

Insider Activity of SCHMERTZLER MICHAEL

The largest purchase of all time was on 2013-06-25 and amounted to 533333 shares of PTC Therapeutics, Inc. for $8M.

The largest sale of all time was on 2010-05-18 and amounted to 829176 shares of Cytokinetics, Incorporated for $2.49M.

Biography of SCHMERTZLER MICHAEL

No biography is available at this moment.

2024-01-08SalePTC Therapeutics, Inc.
PTCT
director
1,500
0.0019%
$27.81$41,715+11.97%
2023-06-07SalePTC Therapeutics, Inc.
PTCT
director
1,000
0.0014%
$44.86$44,860-34.53%
2020-03-16PurchasePTC Therapeutics, Inc.
PTCT
director
20,000
0.0322%
$32.48$649,692+60.5%
2019-01-25PurchasePTC Therapeutics, Inc.
PTCT
director
66,225
0.1217%
$30.20$2M+38.99%
2014-02-19PurchasePTC Therapeutics, Inc.
PTCT
23,000
0.0806%
$24.50$563,500+12.68%
2013-06-25PurchasePTC Therapeutics, Inc.
PTCT
533,333
1.9161%
$15.00$8M+8.52%
2013-03-07PurchasePTC Therapeutics, Inc.
PTCT
269,283
$0$0-63.3%
2010-06-03SaleCytokinetics, Incorporated
CYTK
director
10,764
0.0169%
$3.00$32,292-27.76%
2010-05-27SaleCytokinetics, Incorporated
CYTK
director
115,216
0.1805%
$3.00$345,648-27.33%
2010-05-19SaleCytokinetics, Incorporated
CYTK
director
32,478
0.0516%
$3.00$97,434-25.34%
2010-05-18SaleCytokinetics, Incorporated
CYTK
director
829,176
1.3037%
$3.00$2.49M-25.75%
2010-05-12SaleCytokinetics, Incorporated
CYTK
director
165,476
0.2576%
$3.00$496,428-26.16%
2010-05-11SaleCytokinetics, Incorporated
CYTK
director
73,000
0.1159%
$3.00$219,000-24.66%
2010-05-06SaleCytokinetics, Incorporated
CYTK
director
66,892
0.1069%
$3.03$202,683-24.92%
2010-05-05SaleCytokinetics, Incorporated
CYTK
director
804,200
1.277%
$3.04$2.44M-25.33%
2009-05-21PurchaseCytokinetics, Incorporated
CYTK
director
3.05M
5.7448%
$1.97$6M+68.65%
Total: 16
*Some uncertain data for Preferred Stock share type transactions are shown in italics; for actual data please follow the link
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.